{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:50:08Z","timestamp":1767016208836,"version":"3.37.3"},"reference-count":116,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Immune checkpoint inhibitor (ICPI) therapy unleashes the body's natural immune system to fight cancer. ICPIs improve overall cancer survival, however, the unbridling of the immune system may induce a variety of immune\u2010related adverse events. Neuromuscular immune complications are rare but they can be severe. Myasthenia gravis and inflammatory neuropathy are the most common neuromuscular adverse events but a variety of others including inflammatory myopathy are reported. The pathophysiologic mechanism of these autoimmune disorders may differ from that of non\u2013ICPI\u2010related immune diseases. Accordingly, while the optimal treatment for ICPI\u2010related neuromuscular disorders generally follows a traditional paradigm, there are important novel considerations in selecting appropriate immunosuppressive therapy. This review presents 2 new cases, a summary of neuromuscular ICPI complications, and an approach to the diagnosis and treatment of these disorders. <jats:italic>Muscle Nerve<\/jats:italic> <jats:bold>58<\/jats:bold>: 10\u201322, 2018<\/jats:p>","DOI":"10.1002\/mus.26070","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T17:17:54Z","timestamp":1516209474000},"page":"10-22","source":"Crossref","is-referenced-by-count":62,"title":["Neuromuscular complications of immune checkpoint inhibitor therapy"],"prefix":"10.1002","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2651-2349","authenticated-orcid":false,"given":"Noah A.","family":"Kolb","sequence":"first","affiliation":[{"name":"Department of Neurological Sciences University of Vermont Burlington Vermont USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R","family":"Trevino","sequence":"additional","affiliation":[{"name":"Department of Neuro\u2010oncology MD Anderson Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqar","family":"Waheed","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences University of Vermont Burlington Vermont USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Sobhani","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences University of Vermont Burlington Vermont USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara K.","family":"Landry","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Vermont Medical Center, 1 South Prospect Street, MS 405AR2 Burlington Vermont 05401 USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa A.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences University of Vermont Burlington Vermont USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Hehir","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences University of Vermont Burlington Vermont USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"key":"e_1_2_14_2_1","first-page":"1","volume-title":"Basic immunology","author":"Abbas AK","year":"2015"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"e_1_2_14_7_1","unstructured":"Merk.Keytruda (Pembrolizumab). Highlights of prescribing information [Internet].2014. Available athttps:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. Accessed January 21 2018."},{"key":"e_1_2_14_8_1","unstructured":"Bristol\u2010Meyers Squibb.YERVOY (ipilimumab). Highlights of prescribing information [Internet].2011. Available athttp:\/\/packageinserts.bms.com\/pi\/pi_yervoy.pdf. Accessed January 21 2018."},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw141"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3463"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S126640"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2008.09.010"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2017.02.001"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000186"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.8583"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607116662970"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12139"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12143"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0243-5"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S109453"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30239-5"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25055"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000179942.27777.f8"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25141"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou001"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv158"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12961"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216687389"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25163"},{"key":"e_1_2_14_38_1","first-page":"119","article-title":"Nivolumab for the treatment of malignant melanoma in a patient with pre\u2010existing myasthenia gravis","volume":"78","author":"Maeda O","year":"2016","journal-title":"Nagoya J Med Sci"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.024"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr028"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0092"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23830"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2012-000447"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2548"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000070"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw090"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000070"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25663"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0217"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31827807dd"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318193a206"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1329194"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100007939"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12991"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.2233"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70054-9"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9787-1"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2008.11.010"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410090705"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880120602"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt285"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261706"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004359"},{"key":"e_1_2_14_66_1","unstructured":"Pfizer.Bavencio (avelumab). Highlights of prescribing information [Internet].2017. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761049s000lbl.pdf. Accessed January 21 2018."},{"key":"e_1_2_14_67_1","unstructured":"AstraZeneca.Imfinzi (durvalumab). Highlights of prescribing information [Internet]. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761069s000lbl.pdf. Accessed January 21 2018."},{"key":"e_1_2_14_68_1","unstructured":"Bristol\u2010Meyers Squibb.Opdivo (Nivolumab). Highlights of prescribing information.2014. Available athttps:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf. Accessed January 21 2018."},{"issue":"3","key":"e_1_2_14_69_1","first-page":"30","article-title":"Identification and management of toxicities from immune checkpoint\u2010blocking drugs","volume":"28","author":"Teply BA","year":"2014","journal-title":"Oncology (Williston Park)."},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/857519"},{"key":"e_1_2_14_71_1","unstructured":"Bristol\u2010Meyers Squibb.YERVOY Iipilimumab): serious and fatal immune\u2010mediated adverse reactions [Internet]. Available atwww.yervoy.com\/hcp\/rems.aspx. Accessed January 21 2018."},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_14_74_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.11.1529"},{"key":"e_1_2_14_75_1","unstructured":"Janssen Biotech.REMICADE (Infliximab). Highlights of prescribing information [Internet].1998. Available athttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/103772s5359lbl.pdf. Accessed January 21 2018."},{"key":"e_1_2_14_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20924"},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21280"},{"key":"e_1_2_14_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.5.1253"},{"key":"e_1_2_14_80_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-829595"},{"key":"e_1_2_14_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23445"},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505"},{"key":"e_1_2_14_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615"},{"key":"e_1_2_14_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67665-9"},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182904fcc"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.61.6.736"},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204233261705"},{"key":"e_1_2_14_88_1","first-page":"CD001446","article-title":"Corticosteroids for Guillain\u2010Barr\u00e9 syndrome","volume":"10","author":"Hughes RA","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_14_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15324-X"},{"key":"e_1_2_14_90_1","first-page":"CD010369","article-title":"Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews","volume":"1","author":"Oaklander AL","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_14_91_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001044"},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001833"},{"key":"e_1_2_14_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2010.00284.x"},{"key":"e_1_2_14_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23843"},{"key":"e_1_2_14_95_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402225"},{"key":"e_1_2_14_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.12.025"},{"key":"e_1_2_14_97_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.1207"},{"key":"e_1_2_14_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000158"},{"key":"e_1_2_14_99_1","first-page":"1455","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti\u2010CTLA\u20104","volume":"65","author":"Attia P","year":"2005","journal-title":"Cancer Res"},{"key":"e_1_2_14_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318156e47e"},{"key":"e_1_2_14_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5716"},{"key":"e_1_2_14_102_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"e_1_2_14_103_1","doi-asserted-by":"crossref","first-page":"15S, 9037","DOI":"10.1200\/jco.2009.27.15_suppl.9037","article-title":"Evaluation of the effect of systemic corticosteroids for the treatment of immune\u2010related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity","volume":"27","author":"Amin A","year":"2009","journal-title":"J Clin Oncol"},{"key":"e_1_2_14_104_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4368"},{"key":"e_1_2_14_105_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.1564"},{"key":"e_1_2_14_106_1","article-title":"FDA Approves first cancer treatment for any solid tumor with specific biomarker","author":"Nalley C","year":"2017","journal-title":"Oncology Times"},{"key":"e_1_2_14_107_1","unstructured":"Genentech.Tecentriq (Atezolizumab). Highlights of prescribing information [Internet].2016. Available athttps:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf. Accessed January 21 2018."},{"key":"e_1_2_14_108_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1683"},{"key":"e_1_2_14_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24648"},{"key":"e_1_2_14_110_1","doi-asserted-by":"publisher","DOI":"10.1177\/2324709616674316"},{"key":"e_1_2_14_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25212"},{"key":"e_1_2_14_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00544-6"},{"key":"e_1_2_14_113_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000310"},{"key":"e_1_2_14_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.01.002"},{"key":"e_1_2_14_115_1","first-page":"210","article-title":"A case of new\u2010onset antibody\u2010positive myasthenia gravis in a patient treated with pembrolizumab for melanoma","volume":"60","author":"Alnahhas I","year":"2017","journal-title":"Muscle Nerve"},{"key":"e_1_2_14_116_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000161"},{"key":"e_1_2_14_117_1","doi-asserted-by":"publisher","DOI":"10.1080\/01658107.2017.1291686"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.26070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.26070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T13:03:50Z","timestamp":1694955830000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.26070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1002\/mus.26070"],"URL":"https:\/\/doi.org\/10.1002\/mus.26070","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"type":"print","value":"0148-639X"},{"type":"electronic","value":"1097-4598"}],"subject":[],"published":{"date-parts":[[2018,2,12]]}}}